[Is dopaminergic therapy immunologically rejuvinating? Increased interferon-gamma production with the dopaminergic agent lisuride].
Eighteen patients with advanced Parkinson's disease (n = 13) or dopamine-sensitive dystonia (n = 5) were treated with the dopaminergic agent, lisuride, applied as a long-term subcutaneous infusion. The results were compared with those obtained in a group of younger, and a group of older, healthy volunteers. The liberation of gamma-interferon (gamma-IFN) following mitogenic stimulation of whole blood with phytohemagglutinin (PHA) was highly significantly elevated in comparison with the group of older healthy volunteers, and clearly, but not significantly, elevated in comparison with the younger group. There was no difference between patients with dystonia and those with Parkinson's disease. The effect observed is thus probably due to lisuride. This effect might explain the longer life expectancy and reduced proclivity for infection shown by patients with Parkinson's disease. It needs to be determined whether, on the basis of these initial data, a therapeutic principle for the treatment of diseases that can be directly influenced by gamma-IFN can be derived.
Poehlau
D
D
Neurologische Klinik, Ruhr-Universität Bochum im St.-Josef-Hospital.
Baier
J E
JE
Kovacs
S
S
Gallati
H
H
Suchy
I
I
Will
C
C
Schmutz
T
T
Neumann
H A
HA
Przuntek
H
H
D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007260:Infusion Pumps; D007371:Interferon-gamma / Q000096:biosynthesis*; D008090:Lisuride / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000276:immunology*
D007371:Interferon-gamma; D008090:Lisuride
Macht dopaminerge Therapie immunologisch jung? Erhöhte Interferon-gamma-Produktion unter dem Dopaminergikum Lisurid.